S
688180
vs
S
Shanghai Composite
Over the past 12 months, Shanghai Junshi Biosciences Co Ltd has underperformed Shanghai Composite, delivering a return of +20% compared to the Shanghai Composite's +24% growth.
Stocks Performance
688180 vs Shanghai Composite
Performance Gap
688180 vs Shanghai Composite
Performance By Year
688180 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai Junshi Biosciences Co Ltd
Glance View
Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. emerged as a dynamic player in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of innovative therapies. This company, based in Shanghai, China, has carved a niche in the highly competitive field through its robust pipeline of monoclonal antibodies, small molecule drugs, and therapeutic vaccines. Junshi Biosciences prides itself on its comprehensive R&D capabilities, operating state-of-the-art research facilities that foster significant scientific advancements. Central to its growth strategy is an ongoing commitment to addressing unmet medical needs in oncology, autoimmune, metabolic diseases, and beyond, positioning itself at the forefront of precision medicine. Junshi Biosciences generates revenue through a multifaceted business model that includes partnering with top-tier global pharmaceutical companies, engaging in strategic licensing agreements, and advancing its proprietary products through various stages of clinical trials to eventual market launch. A landmark achievement for the company was the development and commercialization of Toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody approved for multiple indications, which marked a significant milestone in its financial trajectory. Such breakthroughs not only bolster its top-line revenue but also solidify its reputation as an innovator in the global biotechnology landscape. By blending scientific ingenuity with strategic collaborations, Junshi continues to expand its international footprint and deepen its impact on global health.
